Scor upgraded to Overweight from Neutral at JPMorgan. JPMorgan analyst Edward Morris upgraded Scor to Overweight with an unchanged price target of EUR 42. The analyst says the company has an "excellent track record of growth" and that its U.S. mortality and U.S. tax issues now appear to be resolved.
iBeat announced two investments totaling upward of seven figures from SCOR Life & Health Ventures (SCRYY) and Aegon's (AEG) Transamerica Ventures. The investments also include enterprise partnerships and booked revenue for the company's cardiac monitoring smartwatch that will eventually be rolled out to the insurers' agents and policy holders. iBeat will use the new funding to advance product marketing and expansion for its lifesaving Heart Watch. They will also work with life insurers and reinsurers carriers to offer eligible policyholders an iBeat Heart Watch - an everyday watch that monitors real-time changes in heart rate and circulation and looks for any behavior that appears to be unsafe or potentially life threatening. iBeat has received upward of 11,000 pre-orders for its personal safety watch that monitors for potential life-threatening cardiac emergencies and will be shipping orders early this summer.
Scor upgraded to Buy from Hold at Jefferies. Jefferies analyst Philip Kett raised his price target for Scor to Buy saying the company's "highly profitable dominant position" in U.S. Life Reinsurance will become "increasingly apparent" following the three major hurricane losses. The analyst raised his price target for the shares to EUR 38.50.